New research helps address a longstanding question about the inflammatory skin condition psoriasis: Why do skin lesions that have resolved with therapy recur in the same locations after a patient stops using topical steroids?
Stem cells in the skin remember an injury, helping them close recurring wounds faster, researchers have found. The discovery could advance research and treatment of psoriasis and other inflammatory diseases.
The results of a large population study showed an increased risk of developing Psoriatic Arthritis among psoriasis patients exposed to physical trauma, particularly when the trauma involved bone and/or joints.
A new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report. By the end of the trial nearly all of the 31 patients to receive treatment saw dramatic, if not complete, improvement in their symptoms.
A three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4, an abbreviation for the endogenous signaling molecule Interleukin 4. The substance's ability to inhibit inflammation is well known, but its mechanism of action was not fully understood. Scientists have now shown in an animal model and in a study on patients how IL-4 helps against psoriasis at the molecular level.
Researchers have identified genetic variants that are associated with psoriatic arthritis (PsA) but not with psoriasis, in the largest study of PsA ever published.
Genetic variations associated with some modern maladies are extremely old, scientists have discovered, predating the evolution of Neanderthals, Denisovans (another ancient hominin) and contemporary humans.
Scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world. Of the roughly 50,000 proteins in the human body, researchers have zeroed in on four that appear most likely to contribute this chronic disease. The findings dramatically advance efforts to understand how psoriasis develops -- and, in turn, how to stop it.
The annual US cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article.
Solenopsins, the main toxic components of fire ant venom, chemically resemble ceramides, which are lipid-like molecules essential for maintaining for the barrier function of the skin. Solenopsin analogs can reduce skin thickening and inflammation in a mouse model of psoriasis, scientists have shown.
The more the surface area of the body is covered by psoriasis, the greater the risk of death for the patient suffering from the condition, according to a new analysis. Patients with psoriasis on 10 percent or more of their body are at almost double the risk of death.
Biological treatment of psoriasis shows a good efficacy in clinical trials. Since most analyses have focused on short-term outcomes of single biological agents, little has been known about long-term outcomes in clinical practice, where switching between biological agents is common. A study that followed 583 individuals for up to 10 years shows a satisfactory long-term effectiveness of biologic treatments.
Despite mixed evidence recently about an association between atopic dermatitis and cardiovascular disease, a new study that analyzed more than 250,000 medical records suggests there is no link.
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.
There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.
A newly developed tissue scanner allows looking under the skin of psoriasis patients. This provides clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure.
Patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, have reported promising results when they were given a new drug.
